Exelixis (NASDAQ: EXEL)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Exelixis Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Exelixis Company Info
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
News & Analysis
These companies can take investors on a lucrative ride, and all for the price of a few lattes.
Companies that don't make a lot of noise can still make you a lot of money.
Here are the five best biotech ETFs to invest in right now.
Nothing beats a great investment for the price of just a few cups of coffee.
Oh, how some investors love stock buyback programs.
Some relatively low-priced shares can be good buys, too.
Don't be too quick to dismiss this company as a one-trick pony.
These stocks are still bargain-priced but benefit from long-term trends.
EXEL earnings call for the period ending March 31, 2023.
EXEL earnings call for the period ending December 31, 2022.
EXEL earnings call for the period ending September 30, 2022.
EXEL earnings call for the period ending June 30, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.